The Drug Controller General of India (DCGI) has granted permission to manufacture and sell Glenmark pharmaceuticals’ Favipiravir for the treatment of Covid-19.
Similarly, India’s Cipla and Hetero have received emergency marketing approval for another drug, Remdesivir for the treatment of seve
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
